Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytokinetics Seeks ALS Success By Focusing On Lung Function

Executive Summary

Despite an earlier Phase II failure on broader ALS endpoint, biotech thinks it can demonstrate efficacy in slowing lung-function decline in ALS patients.

Advertisement

Related Content

With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup
Seven Clinical Trial Read-Outs Due In Q4
Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Astellas Targets ALS In Expansion Of Cytokinetics Alliance
Ice Bucket $$ poured into Cytokinetics
Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel